Processa Pharmaceuticals, Inc. Other Significant Noncash Transaction, Value of Consideration Given
Processa Pharmaceuticals, Inc. (PCSA) reported Other Significant Noncash Transaction, Value of Consideration Given of $51.11 thousand for the 12-month period ending 2014-12-31, per its 10-K filed 2015-04-14.
Discontinued › Cash Flow › Operating Activities
us-gaap:OtherSignificantNoncashTransactionValueOfConsiderationGiven1 · last filed 2015-08-19
- Processa Pharmaceuticals, Inc. other significant noncash transaction, value of consideration given for the quarter ending 2014-12-31 was $26.83K.
- Processa Pharmaceuticals, Inc. other significant noncash transaction, value of consideration given for the quarter ending 2014-09-30 was $0.00.
- Processa Pharmaceuticals, Inc. other significant noncash transaction, value of consideration given for the quarter ending 2014-06-30 was $10.93K.
- Processa Pharmaceuticals, Inc. other significant noncash transaction, value of consideration given for the quarter ending 2014-03-31 was $13.35K.
- Processa Pharmaceuticals, Inc. other significant noncash transaction, value of consideration given for fiscal 2014 was $51.11K, a 71.08% decline from fiscal 2013.
- Processa Pharmaceuticals, Inc. other significant noncash transaction, value of consideration given for fiscal 2013 was $176.73K.
| Period end | Other Significant Noncash Transaction, Value of Consideration Given 3 month | Other Significant Noncash Transaction, Value of Consideration Given 6 month | Other Significant Noncash Transaction, Value of Consideration Given 9 month | Other Significant Noncash Transaction, Value of Consideration Given 12 month | Other Significant Noncash Transaction, Value of Consideration Given 33 month | Other Significant Noncash Transaction, Value of Consideration Given 36 month |
|---|---|---|---|---|---|---|
| 2014-12-31 | $26.83K derived: 10-K 12 month − 10-Q 9 month · filed 2015-04-14 | $26.83K derived: sum of 2 quarters · filed 2015-04-14 | $37.76K derived: sum of 3 quarters · filed 2015-08-19 | $51.11K 10-K · filed 2015-04-14 | ||
| 2014-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2014-11-13 | $10.93K derived: sum of 2 quarters · filed 2015-08-19 | $24.28K 10-Q · filed 2014-11-13 | |||
| 2014-06-30 | $10.93K derived: 10-Q 6 month − 10-Q 3 month · filed 2015-08-19 | $24.28K 10-Q · filed 2015-08-19 | ||||
| 2014-03-31 | $13.35K 10-Q · filed 2015-05-15 | $190.08K 10-Q · filed 2014-05-14 | ||||
| 2013-12-31 | $176.73K 10-K · filed 2015-04-14 | $176.73K 10-K · filed 2014-03-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AMARIN CORP PLC\UK (AMRN) | $0.005B | -247.24 | |
| Xenetic Biosciences, Inc. (XBIO) | United States | $0.006B | |
| ProPhase Labs, Inc. (PRPH) | United States | $0.006B | -0.06 |
| Dermata Therapeutics, Inc. (DRMA) | United States | $0.005B | -0.62 |
| REVIVA PHARMACEUTICALS HOLDINGS, INC. (RVPH) | United States | $0.005B | |
| Cadrenal Therapeutics, Inc. (CVKD) | United States | $0.004B | -0.90 |
| Pulmatrix, Inc. (PULM) | United States | $0.006B | |
| Lakewood-Amedex Biotherapeutics Inc. (LABT) | United States | $0.004B | |
| Ernexa Therapeutics Inc. (ERNA) | United States | $0.006B | |
| 60 DEGREES PHARMACEUTICALS, INC. (SXTP) | United States | $0.004B | -0.59 |